Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | -3.87% | -4.40% | -12.56% |
May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.56% | 30.23M | |
+18.33% | 83.89B | |
-28.29% | 71.08B | |
+0.99% | 26.77B | |
+3.67% | 17.74B | |
-9.99% | 17.24B | |
+1.86% | 15.6B | |
+79.98% | 13.84B | |
-25.09% | 12.92B | |
+74.41% | 12.87B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023